Acquired von Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 2, 2001, Pages 401-436

  Michiels, Jan Jacques ^a,d   Budde, Ulrich ^b   Van Der Planken, Marc ^a   Van Vliet, Huub H D M ^c   Schroyens, Wilfried ^a   Berneman, Zwi ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Coagulation Laboratory   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Goodheart Institute   (Netherlands)

Author keywords

Acquired von Willebrand syndrome; Chronic lymphocytic leukaemia; Lymphoproliferative disorders; Macroglobulinaemia; Monoclonal gammopathy; Multiple myeloma; Myeloproliferative disorders; Non Hodgkin's lymphoma; Thrombocythaemia; von Willebrand factor

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; AUTOANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8C; BLOOD CLOTTING FACTOR 9; CIPROFLOXACIN; COLLAGEN; DESMOPRESSIN; FIBRINOLYTIC AGENT; GRISEOFULVIN; HETASTARCH; HYALURONIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LEVOTHYROXINE; PARAPROTEIN; PESTICIDE; PLASMA PROTEIN; POLYMER; PREDNISOLONE; PROTEIN INHIBITOR; RISTOCETIN; TETRACYCLINE; UNINDEXED DRUG; VALPROIC ACID; VON WILLEBRAND FACTOR;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; AORTA STENOSIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; BLOOD FLOW; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURGERY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HUMAN; HYPOTHYROIDISM; IMMUNE SYSTEM; LABORATORY DIAGNOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; MOLECULAR WEIGHT; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VALVULAR HEART DISEASE; VON WILLEBRAND DISEASE;

EID: 0034911766     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0141     Document Type: Article

References (148)

1. Acquired von Willebrand disease
2. A revised classification of von Willebrand disease
3. von Willebrand disease
4. Impact, diagnosis and treatment of von Willebrand disease
5. Acquired von Willebrand's disease
6. Acquired von Willebrand's disease
7. Acquired von Willebrand disease: Concise review of occurrence, diagnosis, pathogenesis, and treatment
8. Acquired von Willebrand disease in patients with high platelet counts
9. Clinical significance of inhibitors in acquired von Willebrand syndrome
10. Acquired von Willebrand syndrome: Report of 10 cases and review of the literature
11. Acquired von Willebrand syndrome: From pathophysiology to management
12. Acquired von Willebrand syndrome: Data from an International Registry
13. Recessive inheritance of von Willebrand's disease type I
14. Hypothyroidism as a cause of acquired von Willebrand's disease
15. Acquired von Willebrand's disease in hypothyroidism
16. Hypothyroidism and von Willebrand's disease
17. Hypothyroidism and von Willebrand's disease
18. Acquired von Willebrand's disease and hypothyroidism: Report of a case presenting with menorrhagia
19. Hypothyroidism and acquired von Willebrand disease
20. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism
21. Acquired von Willebrand disease in twins with autoimmune hypothyroidism: Response to desmopressin and I-thyroxine therapy
22. A patient with postpartum primary hypothyroidism and acquired von Willebrand's disease
23. Acquired von Willebrand's disease: A rare manifestation of postpartum thyroiditis
24. Blood coagulation in thyroid dysfunction
25. Thyroid hormone action at the cellular level
26. Acquired von Willebrand disease in a patient with Wilms tumor
27. Acquired von Willebrand's disease in association with Wilms' tumor: Regression following treatment
28. Platelet dysfunction with Wilms tumor and hyaluronic acid
29. Wilms' tumour with acquired von Willebrand's disease
30. Acquired von Willebrand disease in Wilms' tumor patients
31. Acquired von Willebrand's disease in children with Wilms tumor
32. Acquired von Willebrand's syndrome in systemic lupus erythematosus
33. Four cases of acquired von Willebrand's syndrome
34. Acquired von Willebrand's syndrome and systemic lupus erythematosus
35. Antibody-induced von Willebrand syndrome
36. Acquired von Willebrand's syndrome during autoimmune disorder
37. Development of acquired von Willebrand's disease after mixed connective tissue disease
38. Acquired von Willebrand's syndrome with lupus-like serology
39. Autoantibody to von Willebrand factor in systemic lupus erythematosus
40. Acquired von Willebrand's syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin
41. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus
42. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma
43. The reduction of large von Willebrand factor multimers in patients with essential thrombocythemia is related to the platelet count
44. Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia
45. Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy
46. von Willebrand factor and ristocetin
47. Acquired von Willebrand's disease, platelet-release defect and angiodysplasia
48. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand's syndrome
49. Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor
50. Acquired von Willebrand's disease caused by a monoclonal antibody
51. Pathogenesis of antibody-induced acquired von Willebrand syndrome
52. Déficit acquis de facteur Willebrand associé à une gammapathie monoclonale IgG kappa
53. Angiodysplasia of the tongue with acquired von Willebrand's disease
54. Acquired von Willebrand's disease: Demonstration of a circulating inhibitor to the factor VIII complex in four cases
55. Quatre cas de deficit acquis en facteur Willebrand associés a une dysgubulinémie monoclonale
56. Studies on the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies
57. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: An assay for von Willebrand binding by antibody
58. The use of high-dose intravenous gammaglobulin in acquired von Willebrand syndrome
59. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis
60. Prolonged post-operative bleeding due to an acquired von Willebrand syndrome
61. High-dose intravenous gammaglobulin for acquired von Willebrand's disease
62. Acquired type II von Willebrand's disease: Demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment
63. Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy
64. Association of von Willebrand's disease with plasma cell dyscrasia and gastrointestinal angiodysplasia
65. Acquired von Willebrand's disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisolone
66. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate
67. Acquired von Willebrand's disease: Correction of hemostatic defect by high dose intravenous immunoglobulins
68. Expression of GPIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand's disease
69. Gastrointestinal bleeding in acquired von Willebrand's disease: Efficacy of high-dose immunoglobulin where substitution treatments failed
70. Acquired von Willebrand disease caused by an auto-antibody selectively inhibiting the binding of von Willebrand factor to collagen
71. Effectiveness of high-dose intravenous gammaglobulin therapy in acquired von Willebrand's disease
72. High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease
73. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease
74. Association maladie de Willebrand acquise gammapathy monoclonal-angiodysplasie du grêle: Une indication rare des immunoglobulines intraveineuses à forte dose
75. Intravenous gammaglobulin therapy for acquired von Willebrand disease
76. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammapathy of uncertain significance: Comparison of three different therapeutic approaches
77. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma
78. Efficacy of high-dose intravenous gammaglobulin in the management of acquired von Willebrand's disease during orthopedic surgery
79. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor
80. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor
81. Absence of a bleeding tendency in severe acquired von Willebrand's disease
82. Gastrointestinal bleeding, angiodysplasia of the colon and acquired von Willebrand's disease
83. Acquired von Willebrand's disease due to excessive fibrinolysis
84. Acquired von Willebrand's syndrome in the course of Waldenström's disease
85. The efficacy of intensive plasma exchange in acquired von Willebrand's disease
86. Acquired von Willebrand's syndrome and thrombopathy in a patient with chronic lymphocytic leukemia
87. Immunoadsorption for coagulation factor inhibitors
88. Acquired von Willebrand's syndrome
89. Antibody-induced von Willebrand's disease: A newly defined inhibitor syndrome
90. Acquired von Willebrand's disease: Evidence for a quantitative and qualitative factor VIII disorder
91. Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma
92. Demonstration of abnormal factor VIII multimers in acquired von Willebrand's disease associated with a circulating inhibitor
93. Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma
94. Acquired von Willebrand's syndrome and Ehlers-Danlos syndrome presenting with gastrointestinal bleeding
95. Acquired von Willebrand's syndrome
96. Acquired von Willebrand disease associated with an inhibitor to factor VIII antigen and gastrointestinal telangectasia
97. Prolonged remission after life-threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis
98. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor
99. Acquired von Willebrand's syndrome associated with hydatid disease of the spleen
100. Acquired von Willebrand disease in malignant peripheral neurectodermal tumor
101. Acquired von Willebrand's disease following bone marrow transplantation
102. Acquired von Willebrand disease after Epstein-Barr virus infection
103. Acquired von Willebrand disease in monoclonal gammopathies: Effectiveness of high-dose intravenous gammaglobulin
104. A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII
105. Acquired von Willebrand's syndrome associated with hairy cell leukemia
106. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells
107. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma
108. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells
109. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma
110. Loss of the largest von Willebrand factor multimers from plasma of patients with congenital cardiac defects
111. von Willebrand factor and mitral valve prolapse
112. Aortic stenosis and bleeding gastrointestinal angiodysplasia: Is acquired von Willebrand's disease the link?
113. Heart valve stenosis and von Willebrand's factor multimers
114. Reversal of aortic stenosis, bleeding and von Willebrand syndrome by aortic valve replacement
115. Abnormality of von Willebrand factor in patients with hemoglobin E-β thalassemia
116. Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus
117. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation
118. Abnormalities of von Willebrand factor in myeloproliferative disease: A relationship with bleeding diathesis
119. Acquired von Willebrand disease in patients with polycythemia vera
120. Unique multimeric pattern of von Willebrand factor in patients with benign monoclonal gammopathy
121. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders
122. Platelet von Willebrand factor in myeloproliferative syndromes
123. Hämostasestörung mit verminderter Aktivität des von Willebrand-Faktors bei myeloproliferativen Syndromen
124. Acquired von Willebrand's disease in the myeloproliferative syndrome
125. Essential thrombocythemia with acquired von Willebrand's
126. Acquired von Willebrand disease in association with essential thrombocythemia: Regression following treatment
127. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia
128. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome
129. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythemia: Normalization after cytoreduction of the increased platelet count
130. Histopathology of erythromelalgia in thrombocythemia
131. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia
132. Aspirin in essential thrombocythemia: Status quo and quo vadis
133. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera
134. Prevention and treatment of thrombotic complications in essential thrombocythemia: Efficacy and safety of aspirin
135. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia
136. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia
137. Erythromelalgic, thrombotic and hemorrhagic thrombocythemia
138. Hemorrhagic thrombocythemia. A critical review
139. Acquired Morbus von Willebrand
140. Induction of von Willebrand disease type I by valproic acid
141. Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy
142. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin
143. Hydroxyethyl starch accentuates von Willebrand's disease
144. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: Ristocetin cofactor activity
145. Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch
146. A severe coagulopathy following replacement with hydroxyethyl starch in a Jehovah's witness
147. Hydroxyethyl starch induced acquired von Willebrand's disease
148. Coagulation disorders caused by hydroxyethyl starch